Lung Cancer
Conditions
Brief summary
Immunotherapy effectiveness and optimal combination strategy in lung cancers with EGFR uncommon and 20ins mutations was unclear. Based on 627 lung adenocarcinoma patients harboring EGFR mutations and receiving immunotherapy, we reported that patients with EGFR uncommon mutations had better response to immunotherapy, than EGFR 19del/L858R or 20in mutations. Immunotherapy monotherapy or plus chemotherapy was identified as better combination strategy for EGFR uncommon or 20ins mutations, respectively. Higher tumor mutation burden, more M1 macrophage, less Tregs and M2 macrophages infiltration, but not PD-L1 expression was found to be associated with EGFR uncommon mutations, compared to EGFR 19del/L858R or 20in mutations. These findings revealed diverse response and optimal combination strategy of lung adenocarcinoma patients harboring EGFR mutation subtypes, promoting rethinking about current immunotherapy application and prolonging survivals of them.
Interventions
OTHERSurvival analysis
Immunotheray responses and long-term survival were evaluated in classical and other EGFR-mutant lung adenocarcinomas
Sponsors
Haiquan Chen
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. age≥18 years, 2. advanced or recurrent LUAD confirmed by pathology, 3. harboring EGFR mutations confirmed by super amplification refractory mutation system (super-ARMS) or next-generation sequencing (NGS), 4. receiving anti-PD-(L)1 antibody therapy at least once, 5. Radiologically evaluable according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1)
Exclusion criteria
\-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Tumor response | From date of initial treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months | Partial response, disease progression, and stable disease were defined according to the RECIST v1.1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survivals | 5 years | Progression-free survivals were defined as the time from the initial treatment to the date of disease progression or death |
Countries
China
Outcome results
None listed